Up there in the annals of multinational corporations doing heinous things in the name of obscene profits comes the German-based Bayer's response to India ending the pharma giant's monopoly for a pricey new anti-cancer drug, thus allowing a small Indian company to make a generic version that poor sick people can afford. A year of Bayer's Nexavar costs $96,000 in the U.S. and $69,000 in India, 41 times the per capita income; India's Natco Ltd. made it for $177 a year. Outraged Bayer officials...